 prospect random trial combin half-dos tissue-typ plasminogen activ streptokinas full-dos tissue-typ plasminogen activ kentucki acut myocardi infarct trial kamit group background potenti benefit combin thrombolyt agent treatment myocardi infarct remain uncertain small pilot studi half-dos tissue-typ plasminogen activ t-pa streptokinas SK high rate infarct vessel patenc low rate reocclus cost full-dos method and result prospect trial patient hour myocardi infarct combin half-dos mg t-pa streptokinas MU hour convent dose t-pa mg hour acut patenc angiographi minut angioplasti fail thrombolysi heparin aspirin regimen follow-up catheter day acut patenc t-pa/sk t-pa alon angioplasti fail thrombolysi acut patenc group deplet serum fibrinogen level t-pa/sk t-pa alon hour versu mg/dl hour therapi versu mg/dl reocclus reinfarct emerg bypass surgeri t-pa/sk group greater myocardi salvag appar t-pa/sk group infarct zone function day sd/chord versu sd/chord t-pa in-hospit mortal seriou bleed similar group conclus result expens regimen half-dos t-pa SK yield superior patenc ventricular function trend reocclus convent dose t-pa